AstraZeneca Dividendos y recompras

Dividendo controles de criterios 4/6

AstraZeneca es una empresa que paga dividendos con una rentabilidad actual de 2.36% que está bien cubierta por los beneficios.

Información clave

2.4%

Rentabilidad por dividendo

0.02%

Rendimiento de la recompra

Rendimiento total para el accionista	2.4%
Rendimiento futuro de los dividendos	2.7%
Crecimiento de los dividendos	-8.6%
Próxima fecha de pago de dividendos	n/a
Fecha ex dividendo	n/a
Dividendo por acción	US$3.011
Ratio de pago	71%

Últimas actualizaciones de dividendos y recompras

No hay actualizaciones

Recent updates

Estabilidad y crecimiento de los pagos

Obteniendo datos sobre dividendos

Dividendo estable: El pago de dividendos de AZN ha sido volátil en los últimos 10 años.

Dividendo creciente: El pago de dividendos de AZN ha aumentado en los últimos 10 años.

Rentabilidad por dividendo vs. Mercado

Rentabilidad por dividendo de AstraZeneca vs. Mercado

¿Cómo se compara la rentabilidad por dividendo de AZN con la del mercado?
Segmento	Rentabilidad por dividendo
Empresa (AZN)	2.4%
Suelo de mercado 25% (US)	1.4%
Techo de mercado 25% (US)	4.3%
Media de la industria (Pharmaceuticals)	2.5%
Analista de previsiones (AZN) (hasta 3 años)	2.7%

Dividendo destacado: El dividendo de AZN(2.36%) es más alto que el 25% inferior de los pagadores de dividendos del mercado US (1.39%).

Alto dividendo: El (2.36%) del dividendo de AZN es bajo en comparación con el 25% de los principales pagadores de dividendos del mercado US (4.32%).

Pago de beneficios a los accionistas

Cobertura de los beneficios: Con su razonable ratio de pago (70.9%), los pagos de dividendos de AZN están cubiertos por los beneficios.

Pago en efectivo a los accionistas

Cobertura de flujo de caja: Con su razonable ratio de pago en efectivo (66.5%), los pagos de dividendos de AZN están cubiertos por los flujos de caja.

AstraZeneca Dividendos y recompras

Dividendo controles de criterios 4/6

Información clave

Últimas actualizaciones de dividendos y recompras

Recent updates

AstraZeneca: Strong Growth Potential And Market Volatility Offer Opportunity

AstraZeneca PLC Revises Earnings Guidance for the Fiscal Year 2024

Daiichi Sankyo and AstraZeneca Submits New Biologics License Application for Accelerated Approval in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Amgen and AstraZeneca Announce Positive Top-Line Results from the Phase 3 WayPOINT Trial in Patients with Chronic Rhinosinusitis with Nasal Polyps

AstraZeneca: Contrarian Buy After The China Challenge (Rating Upgrade)

Daiichi Sankyo and AstraZeneca Announce Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer

Astrazeneca plc Announces Astrazeneca and Ionis' Wainzua (Eplontersen) Recommendation for Approval by the Committee for Medicinal Products for Human Use (CHMP) in the European Union

AstraZeneca PLC Announces AIRSUPRA (Albuterol/Budesonide) Demonstrated Statistically Significant and Clinically Meaningful Reduction in the Risk of Severe Exacerbations in Patients with Intermittent or Mild Persistent Asthma in BATURA Phase III Trial

AstraZeneca PLC Announces AIRSUPRA (Albuterol/Budesonide) Demonstrated Statistically Significant and Clinically Meaningful Reduction in the Risk of Severe Exacerbations in Patients with Intermittent or Mild Persistent Asthma in BATURA Phase III Trial

Astrazeneca’S CALQUENCE® (acalabrutinib) Receives Priority Review in the US for Patients with Untreated Mantle Cell Lymphoma

Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Cas Datifan in Combination with Volrustomig in Renal Cell Carcinoma

Astrazeneca and Daiichi Sankyo's Supplemental Biologics License Application for ENHERTU (Fam-Trastuzumab Deruxtecan-nxki) Accepted and Granted Priority Review in the US

Enhertu Grants Daiichi Sankyo and Astrazeneca Priority Review in the U.S. for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Who Have Received At Least One Line of Endocrine Therapy

Astrazeneca PLC Tagrisso Receives US Approval in Unresectable Stage III EGFR-Mutated Lung Cancer Lung Cancer

Datopotamab Deruxtecan Significantly Extended Progression-Free Survival Versus Chemotherapy in Patients with Hr Positive, Her2 Low or Negative Breast Cancer in Patients with Hr Positive, Her2 Low or Negative Breast Cancer

AstraZeneca: Buy This Big Pharma Stock At A Discount Now

AstraZeneca PLC’s FluMist Receives Approval for Self-Administration in the US

AstraZeneca PLC's Fasenra Approves in the US for Eosinophilic Granulomatosis with Polyangiitis

AstraZeneca Announces Positive Results from the Niagara Phase III Trial

Daiichi Sankyo Company Limited and Astrazeneca Announces Enhertu Showed Substantial Clinical Activity in Patients with Her2 Positive Metastatic Breast Cancer and Brain Metastases

AstraZeneca: Dato-DXd Should Still Be Approved In Q4 Despite Underwhelming Data

Astrazeneca Presents Interim Results from the Randomized NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Present At the WCLC 2024

Astrazeneca's Imfinzi Receives Approval in US for the Treatment of Resectable Non-Small Cell Lung Cancer Before and After Surgery

Astrazeneca's Supplemental Biologics License Application for Imfinzi (Durvalumab) Granted Priority Review and Breakthrough Therapy Designation for Patients with Limited-Stage Small Cell Lung Cancer in the US

Astrazeneca Announces Positive High-Level Results from an Interim Analysis of the Amplify Phase III Trial

FDA Advisory Committee Reviewes Astrazeneca's Imfinzi for Treatment of Resectable Non-Small Cell Lung Cancer Based on Aegean Phase III Trial Results

Astrazeneca plc Announces Voydeya Approved in Canada as Add-On Therapy to Ravulizumab or Eculizumab for Adults with the Rare Disease PNH Who Have Residual Hemolytic Anemia Due to Extravascular Hemolysis

Estabilidad y crecimiento de los pagos

Rentabilidad por dividendo vs. Mercado

Pago de beneficios a los accionistas

Pago en efectivo a los accionistas

Descubre empresas que pagan buenos dividendos